UNASSIGNED:比较佐剂质子束与目的探讨碳离子束放疗在头颈部癌根治术后放疗中的应用价值.
UNASSIGNED:回顾性分析了2015年10月至2019年3月在上海质子和重离子中心(SPHIC)进行完全手术切除后接受辅助PBRT的38例头颈部癌症患者的数据。总的来说,18例患者接受了辅助质子束治疗(54-60GyE/27-30分),20例接受了辅助碳离子放射治疗(CIRT)(54-60GyE/18-20分)。使用Kaplan-Meier分析计算生存率。根据不良反应通用术语标准(4.03版)评估毒性。
UNASSIGNED:中位随访时间为21(范围,3-45)个月,2年总生存期(OS),无进展生存期(PFS),局部区域无复发生存率(LRRFS)和无远处转移生存率(DMFS)分别为93.3%,87.4%,94.1%,90.7%,分别,对于整个队列。质子束治疗后的比率与CIRT为94.1%与91.7%(P=0.96),88.1%vs.86.2%(P=0.96),94.4%vs.93.3%(P=0.97),和88.1%vs.92.9%(P=0.57),分别。此外,18例(88.9%)患者在质子束治疗后出现急性I/II级皮炎(13例I级;3例II级),20例患者中只有7例(35%)在CIRT后出现急性I级皮炎(P=0.001).质子和碳离子病例中急性I/II级粘膜炎和口干的发生率为45%。55%(P=0.75)和56%。50%(P=0.87)。
未经批准:头颈部癌根治性手术切除后的辅助质子束治疗和CIRT提供了令人满意的治疗效果,但是两种放射治疗技术之间没有显着差异。然而,与质子束治疗相比,佐剂CIRT与更有利的急性毒性曲线相关,观察到急性皮炎的频率和严重程度显着降低。
UNASSIGNED: To compare the efficacy and toxicity of adjuvant proton beam vs. carbon-ion beam radiotherapy for head and neck cancers after radical resection and to explore the value of particle beam radiotherapy (PBRT) in postoperative radiotherapy for head and neck cancers.
UNASSIGNED: Data from 38 head and neck cancer patients who received adjuvant PBRT after complete surgical resection at the Shanghai Proton and Heavy Ion Center (SPHIC) between October 2015 and March 2019 were retrospectively analyzed. In total, 18 patients received adjuvant proton beam therapy (54-60 GyE/27-30 fractions) and 20 received adjuvant carbon-ion radiotherapy (CIRT) (54-60 GyE/18-20 fractions). Survival rates were calculated using Kaplan-Meier analysis. Toxicity was evaluated according to the Common Terminology Criteria for Adverse Effects (version 4.03).
UNASSIGNED: With a median follow-up time of 21 (range, 3-45) months, the 2-year overall survival (OS), progression-free survival (PFS), local-regional recurrence-free survival (LRRFS) and distant metastasis-free survival (DMFS) rates were 93.3%, 87.4%, 94.1%, and 90.7%, respectively, for the entire cohort. The rates after proton beam therapy vs. CIRT were 94.1% vs. 91.7% (P=0.96), 88.1% vs. 86.2% (P=0.96), 94.4% vs. 93.3% (P=0.97), and 88.1% vs. 92.9% (P=0.57), respectively. Furthermore, 16 of the 18 (88.9%) patients developed acute grade I/II dermatitis (13 grade I; 3 grade II) after proton beam therapy, and only 7 of the 20 (35%) patients developed acute grade I dermatitis after CIRT (P=0.001). The incidence of acute grade I/II mucositis and xerostomia in proton and carbon ion cases were 45% vs. 55% (P=0.75) and 56% vs. 50% (P=0.87) respectively.
UNASSIGNED: Adjuvant proton beam therapy and CIRT after radical surgical resection for head and neck cancers provided satisfactory therapeutic effectiveness, but no significant difference was observed between the two radiotherapy technologies. However, adjuvant CIRT was associated with a more favorable acute toxicity profile as compared to proton beam therapy with significantly lower frequency and severity of acute dermatitis observed.